Sap Biotech India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-07-2024
- Paid Up Capital ₹ 0.10 M
as on 02-07-2024
- Company Age 10 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -48.51%
(FY 2023)
- Profit -605.22%
(FY 2023)
- Ebitda -219.25%
(FY 2023)
- Net Worth -83.77%
(FY 2023)
- Total Assets -17.36%
(FY 2023)
About Sap Biotech India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashwani Mehta and Priyanka Dua serve as directors at the Company.
- CIN/LLPIN
U24100HR2014PTC053153
- Company No.
053153
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurgaon, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sap Biotech India Private Limited offer?
Sap Biotech India Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, Respiratory System Drugs, Anti Asthma Drug, Pain Relief Drugs & Pharmaceuticals, Aceclofenac, Common Disease Medicines, Allopathic Cough Syrup.
Who are the key members and board of directors at Sap Biotech India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashwani Mehta  | Director | 22-Aug-2014 | Current |
| Priyanka Dua | Director | 01-May-2023 | Current |
Financial Performance of Sap Biotech India.
Sap Biotech India Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48.51% decrease. The company also saw a substantial fall in profitability, with a 605.22% decrease in profit. The company's net worth observed a substantial decline by a decrease of 83.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sap Biotech India?
In 2023, Sap Biotech India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Asterisk Laboratories India Private LimitedActive 10 years 10 monthsAshwani Mehta and Priyanka Dua are mutual person
Gracia Lifesciences India Private LimitedActive 12 years 4 monthsAshwani Mehta and Priyanka Dua are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sap Biotech India?
Unlock and access historical data on people associated with Sap Biotech India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sap Biotech India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sap Biotech India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
